Towards a framework for the generation of enhanced attack/background network traffic for evaluation of network-based intrusion detection systems.

From a Belgian payer perspective, PP with pegfilgrastim appears cost effective compared to other prophylaxis strategies in patients with stage II breast cancer or NHL at a €30,000/QALY threshold.